Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Inclusion Criteria * Subjects must have ADHD that meets the DSM-IV criteria * Aged 6 to 16 years. * Subjects must not have taken any medication used to treat ADHD. * Laboratory results must show no significant abnormalities * Baseline ECG results must not show an abnormality * Subjects must be able to swallow capsules. * Subjects must be of normal intelligence. Exclusion Criteria * Weigh less than 20 kg or more than 60 kg at study entry. * Subjects who, after an adequate trial with methylphenidate or amphetamine experience some benefit in ADHD signs and symptoms are excluded from participating. * Have a history of Bipolar I or II disorder, psychosis, or PDD. * Meet DSM-IV criteria for an anxiety disorder. * Have a history of any seizure disorder. * Patients at serious suicidal risk. * Patients with narrow angle glaucoma * Subjects who have a history of severe allergies . * Have a history of alcohol or drug abuse within the past 3 months * Screen positive for drugs of abuse not prescribed by a physician. * Have cardiovascular disease and an increased heart rate and blood pressure. * Have a medical condition that would increase sympathetic nervous system activity markedly or who are taking a medication on a daily basis. * Have severe gastrointestinal narrowing * Are during the study time likely to need psychotropic medications. * Are likely to begin a structured psychotherapy aimed at ADHD symptoms. * Have used a monoamine oxidase inhibitor (MAOI) during the 2 weeks * Female subjects who are pregnant or who are breast-feeding. * Are investigative site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. * Are, in the opinion of the investigator, unsuitable in any other way to participate in this study. * Are employed by Lilly.